Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01835626 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
A Phase 2 study of Skin Cancer and Locally Advanced Basal Cell Carcinoma, sponsored by Sue Yom.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT01835626 is a Phase 2 study of Skin Cancer and Locally Advanced Basal Cell Carcinoma that has completed, run by Sue Yom. The registered enrollment target is 24 participants, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01835626, a Phase 2 study of Skin Cancer and Locally Advanced Basal Cell Carcinoma, has completed, sponsored by Sue Yom.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
Chemotherapy, radiation therapy, and surgery are standard treatments for basal cell carcinoma at most institutions. The purpose of this study is to determine whether adding vismodegib to radiation (chemoradiotherapy) is safe and tolerable. The purpose of this study is to assess the safety and tolerability of combined radiation therapy and vismodegib. This combination may increase the chances of the tumors being destroyed or unable to spread to other parts of the body in people with locally advanced basal cell carcinoma of the head and neck.
Conditions Studied
Interventions
- DRUG Vismodegib
- RADIATION Radiation therapy
Study Locations (2)
California
- University of California, San Francisco - San Francisco
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-05 |
| Est. Completion | 2019-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01835626
The ClinicalTrials.gov registry entry for NCT01835626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Sue Yom, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Skin Cancer appearing as the primary indexed condition, and to 2 interventions - of which Vismodegib is the first listed.
NCT01835626 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT01835626 about?
NCT01835626 is a clinical study titled "Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma". Chemotherapy, radiation therapy, and surgery are standard treatments for basal cell carcinoma at most institutions. The purpose of this study is to determine whether adding vismodegib to radiation (chemoradiotherapy) is safe and tolerable. The purpose of this study is to assess the safety and tolera...
What is the current status of trial NCT01835626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2013-05. Estimated completion is 2019-09-10.
What conditions does trial NCT01835626 study?
This clinical trial studies the following conditions: Skin Cancer, Locally Advanced Basal Cell Carcinoma, Cutaneous Malignancy.
What interventions are being tested in trial NCT01835626?
The interventions under investigation include: Vismodegib (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01835626?
This trial is sponsored by Sue Yom, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01835626 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Study of Talabostat and Cisplatin in Advanced Melanoma
COMPLETED · Phase 2
-
Phase II Trial of Allovectin-7® for Metastatic Melanoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.